Gesendet von Meddrug (89.28.21.131) on February 08, 2010 at 11:50:36:
als Antwort auf: Drug Story posted by Drug Story on September 02, 2009 at 06:58:24:
The U.S. Food and Drug Administration (FDA) has approved Cymbaltaź (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE: LLY) announced.
The efficacy and safety of Medecine for the maintenance treatment of GAD were established in a double-blind, placebo-controlled trial. Patients with GAD who initially had responded to treatment with Cymbalta 60-120 mg/day during a 26-week open-label phase were randomly assigned to receive Cymbalta 60-120mg/day (216 patients) or placebo (213 patients).